This study will assess the feasibility to assess practicality of early weight loss medication usage in adolescent patients post-VSG with inadequate weight loss. Participants who enroll in the study will be prescribed off-label use of weight loss medications for a period of up to 1 year.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Topiramate (starting dose 25 mg daily, max dose 100 mg daily)
Phentermine (starting dose 8 mg, max dose 16 mg)
Stanford University
Palo Alto, California, United States
Number of participants who are able to consent for off-label medication use as a measure of feasibility
Time frame: Up to 1 year
Average daily rate of compliance with medication administration
Time frame: Up to 1 year
Percent change from baseline in % BMI
Time frame: Baseline (initiation of medication), 1 year
Type of weight loss medication prescribed
Type of weight loss medication prescribed, according to type and dose
Time frame: Up to 1 year
Number of participants experiencing side effects
Time frame: Up to 1 year
Timing of the implementation of off-label medications after vertical sleeve gastrectomy
Time frame: Up to 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.